
Dan Lu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9440190/publications.pdf Version: 2024-02-01



DANLU

#	Article	IF	CITATIONS
1	Modelâ€Informed Therapeutic Dose Optimization Strategies for Antibody–Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration–Approved Antibody–Drug Conjugates?. Clinical Pharmacology and Therapeutics, 2021, 110, 1216-1230.	2.3	25
2	Clinical pharmacology of vc-MMAE antibody–drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies. MAbs, 2020, 12, 1699768.	2.6	21
3	Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibodyâ€Drug Conjugates. Journal of Clinical Pharmacology, 2020, 60, S105-S119.	1.0	8
4	Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer. Cancer Chemotherapy and Pharmacology, 2019, 84, 175-185.	1.1	3
5	Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Clinical Cancer Research, 2017, 23, 1167-1176.	3.2	77
6	Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncology, The, 2015, 16, 704-715.	5.1	272
7	Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. Cancer Chemotherapy and Pharmacology, 2014, 74, 399-410.	1.1	69
8	Strategies to address drug interaction potential for antibody–drug conjugates in clinical development. Bioanalysis, 2013, 5, 1115-1130.	0.6	19
9	Drug Interaction Potential of Trastuzumab Emtansine (T-DM1) Combined with Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer. Current Drug Metabolism, 2012, 13, 911-922.	0.7	41
10	Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemotherapy and Pharmacology, 2012, 69, 1229-1240.	1.1	230